New research reveals that patients who discontinue blockbuster weight-loss injections like Mounjaro or Wegovy tend to recover reduced body mass at a significantly accelerated pace than those who halt traditional diet and exercise programs.
Research printed in a prominent health publication shows that while obese people frequently drop substantial amounts of their body weight while using the jabs, the weight returns at an average rate of 0.8 kg per month upon discontinuation.
"Users buying such medications must be cognizant of the risk of quick rebound weight gain when the treatment concludes," cautioned expert Dr. Susan Jebb.
Such speed of recovery means a reversion to pre-treatment weight in about one and a half years.
Comparing Therapies
The study, which reviewed dozens of trials involving over 9,000 of patients, contrasted the outcomes of these new drugs with older methods.
Researchers note that people who lose weight through diet and exercise typically see a slower creep back—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Doctors believe the mechanism of the jabs explains the accelerated rebound.
The injections mimic a body's own chemical called glucagon-like peptide-1, which moderates feelings of fullness.
"Sustained high doses of the hormone concentrations several times higher than normal could lead to the system to generate a reduced amount of its own natural GLP-1, and may also lessen responsiveness to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' results in hunger is unsuppressed, making overeating far more likely."
An Ongoing Issue?
The NHS advise the jabs for people with weight-linked medical conditions, accompanied by recommended diet and exercise modifications.
Many experts say that, considering the significant potential of weight regain, the treatment is often ongoing.
This perspective is echoed by pharmaceutical companies, who say that the findings "highlight the long-term nature of excess weight," similar to managing diseases like diabetes.
User Testimonies
Individuals who have discontinued the medication report a powerful resurgence of cravings.
"It was like something that goes on and you're instantly extremely hungry," described a patient.
This difficulty is worsened if patients have not established sustainable lifestyle or habit changes during treatment.
Growing Use
Figures indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Adoption is greater among women than men.
- The middle-aged demographic shows the greatest level of interest.
- A large proportion access the drugs through private healthcare rather than public health services.
Ultimately, clinicians emphasize that while GLP-1 drugs are powerful tools for weight loss, they are not a permanent solution and maintained weight loss relies on combined lifestyle support.
